Yutrepia's Future in Doubt as Liquidia Sheds $3.18B on Patent Loss

For biotech and pharma operators, this ruling strikes at the heart of commercial strategy: Yutrepia was already cutting nebulized Tyvaso sales by 18% and drives nearly all of Liquidia's revenue. Whether the court blocks Yutrepia or lets it continue under a royalty will determine not just a patent fight but near-term treatment access and competitive share in PH-ILD.

On Wednesday, September 30, 2026, a Delaware federal judge ruled that two claims of U.S. Patent No. 11,826,327 are valid. The patent, as reported by Bloomberg Law, covers inhaled dry-powder treprostinil for pulmonary hypertension associated with interstitial lung disease, or PH-ILD. Liquidia had already admitted infringement, so the validity finding established infringement liability in one stroke. The market reaction was immediate and lopsided: United Therapeutics closed at $541.89, up 12.55%, while Liquidia fell to $30.26, down 57.19%, erasing roughly $3.18 billion in market value. This is not merely a patent priority dispute; it is a decision that directly threatens Liquidia's flagship product Yutrepia while strengthening United Therapeutics' Tyvaso franchise.

“

The market reaction was immediate and lopsided: United Therapeutics closed at $541.89, up 12.55%, while Liquidia fell to $30.26, down 57.19%, erasing roughly $3.18 billion in market value.

The underlying competitive context matters. Liquidia won FDA approval for Yutrepia, an inhaled dry-powder formulation of treprostinil, positioning it as a direct challenger to United Therapeutics' nebulized Tyvaso. Nebulized Tyvaso sales fell 18% year over year in the second quarter, evidence that Liquidia was already capturing patients in the PH-ILD market. Yutrepia drives nearly all of Liquidia's revenue, while the company's pipeline candidate just began Phase 3 enrollment. That concentration explains the severity of the stock collapse. Investors had priced Yutrepia's freedom to compete as central to Liquidia's near-term and mid-term value. The court's validity finding upended that assumption, though it did not fully resolve the commercial threat.

From a legal standpoint, the current posture is important. Liability has been decided—validity and infringement are resolved—but remedies are not. United Therapeutics has requested an injunction that would restrict Yutrepia's availability, and both sides must propose remedies within about a week. The court has not yet decided whether to grant an injunction, impose royalties, or award damages, and final judgment remains pending. Liquidia itself said its potential damages cannot currently be reasonably estimated. This uncertainty leaves meaningful downside and upside scenarios for both companies. If the court issues an injunction, Yutrepia may be forced from the market, ceding PH-ILD patients back to Tyvaso and boosting United Therapeutics' revenue trajectory. If instead the court elects an ongoing royalty, Yutrepia could remain available, limiting the competitive advantage United Therapeutics just won and preserving Liquidia's commercial lifeblood albeit at a cost.

The appeal path also keeps the matter alive. Liquidia's chief executive, Roger Jeffs, said the company respectfully disagrees and is fully prepared to pursue all available appellate options. Liquidia concurrently plans to ask the FDA to remove the PH-ILD indication from Yutrepia's label, presumably to avoid continued infringement and damages exposure. That pharmaceutical regulatory workaround adds another layer. If the FDA grants a label change, it might narrow the product's use but could preserve its viability in other indications, depending on applicable approvals. However, the immediate problem is that Yutrepia's entire commercial role is tied to the very indication now at issue.